Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

A senior executive at BeiGene is under investigation by Chinese authorities, multiple local media outlets report. | A senior ...

Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting | This week on "The Top Line," ...

The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment ...

The CDC seems to be taking an “if it ain’t broke” approach to its annual flu vaccine push. | The CDC seems to be taking an ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Rentschler acquired the Milford facility—its entry into the U.S. market—from Shire in 2019. The CDMO also operates a third ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...